KI-Beratung Beta

Produktbild: Medicinal Chemistry Approaches to Personalized Medicine
Band 59

Medicinal Chemistry Approaches to Personalized Medicine

Fr. 172.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

27.12.2013

Abbildungen

12 Farbabb.

Herausgeber

Karen Lackey + weitere

Verlag

Wiley-VCH

Seitenzahl

408

Maße (L/B/H)

2.6/16.4/24.3 cm

Gewicht

1004 g

Sprache

Englisch

ISBN

978-3-527-33394-3

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

27.12.2013

Abbildungen

12 Farbabb.

Herausgeber

Verlag

Wiley-VCH

Seitenzahl

408

Maße (L/B/H)

2.6/16.4/24.3 cm

Gewicht

1004 g

Sprache

Englisch

ISBN

978-3-527-33394-3

Herstelleradresse

Wiley-VCH GmbH
Boschstr. 12
69469 Weinheim
Deutschland
Email: trade@wiley.com
Url: www.wiley-vch.de
Fax: +49 6201 606328

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Medicinal Chemistry Approaches to Personalized Medicine
  • ForewordPrefaceA Personal ForewordAcronymsMEDICINAL CHEMISTRY APPROACHES TO CREATING TARGETED MEDICINESIntroductionRole of Medicinal Chemistry in Drug DiscoveryEvolution of Molecular Design for Subsets of PatiensCombinations for Effective TherapiesBiomarkers in Targeting PatiensEmerging Field of EpigeneticsSystems Chemical BiologyTheranostics and Designing Drug Delivery SystemsRapid Progress in Further Personalizing Medicine ExpectedDISCOVERY OF PREDICTIVE BIOMARKERS FOR ANTICANCER DRUGSIntroduction"Oncogene Addiction" as a Paradigm for Clinical Implementation of Predictive BiomarkersCancer Cell Lines as a Model System for Discovery of Predictive BiomarkersModeling Drug Resistance to Discover Predictive BiomarkersDiscovery of Predictive Biomarkers in the Context of Treatment CombinationsDiscovery of Predictive Biomarkers for Antiangiogenic AgentsGene Expression Signatures as Predictive BiomarkersCurrent Challenges in Discovering Predictive BiomarkersFuture PerspectiveCRIZOTINIBIntroductionDiscovery of Crizotinib (PF-02341066)Kinase Selectivity of CrizotinibPharmacology of CrizotinibHuman Clinical Efficacies of CrizotinibSummaryDISCOVERY AND DEVELOPMENT OF VEMURAFENIB: FIRST-IN-CLASS INHIBITOR OF MUTANT BRAF FOR THE TREATMENT OF CANCERBackgroundDiscovery and Development of Vemurafenib (PLX4032)PharmacologyClinical Efficacy and SafetyCompanion Diagnostic (cobas 4800) DevelopmentSynthesisSummaryTARGETING BASAL-CELL CARCINOMA: DISCOVERY AND DEVELOPMENT OF VISMODEGIB (GDC-0449), A FIRST-IN-CLASS INHIBITOR OF THE HEDGEHOG PATHWAYIntroductionHedgehog and Basal-Cell CarcinomaCyclopamine as an SMO AntagonistSmall-Molecule Inhibitors of SMOPreclinical Characterization of VismodegibVismodegib Clinical Experience in Phase 1G-QUADRUPLEXES AS THERAPEUTIC TARGETS IN CANCERIntroductionQuadruplex FundamentalsGenomic QuadruplexesQuadruplexes in Human TelomeresQuadruplexes as Anticancer Targets - Evidence from In Vivo StudiesNative Quadruplex StructuresQuadruplex-Small-Molecule StructuresDeveloping Superior Quadruplex-Binding LigandsConclusionsIDENTIFYING ACTIONABLE TARGETS IN CANCER PATIENSIntroduction and BackgroundOverview of Genomic Sequencing and Its Impact on the Identification of Actionable MutationsActionable Targets by Clinical Molecular Profiling: The OICR/PMH ExperienceSome Exeriences of Other Clinical Oncology Molecular Profiling StudiesIdentifying Secondary and Novel Mutations through Molecular ProfilingUnderstanding and Targeting Resistance Mutations: A Challenge and an Opportunity for NGSConcluding Remarks and Future PerspectivesDNA DAMAGE REPAIR PATHWAYS AND SYNTHETIC LETHALITYIntroductionDNA Damage ResponseSynthetic LethalityLead Case Study: PARP InhibitorsAdditional Case StudiesScreening for Synthetic LethalityContextual Synthetic Lethality ScreeningCancer Stem CellsConclusions and Future DirectionsAMYLOID CHEMICAL PROBES AND THERANOSTICS: STEPS TOWARD PERSONALIZED MEDICINE IN NEURODEGENERATIVE DISEASESIntroductionAmyloid Plaques as the Biomarker in ADDetecting Amyloid Plaques in Patiens: From Alois Alzheimer to Amyvid and BeyondSame Causes, Same Imaging Agents?Theranosticcs in ADConclusions and PerspectivesFROM HUMAN GENETICS TO DRUG CANDIDATES: AN INDUSTRIAL PERSPECTIVE ON LRRK2 INHIBITION AS A TREATMENT FOR PARKINSON'S DISEASEIntroductionBiochemical Studies of LRRK2 FunctionCellular Studies in LRRK2 FunctionAnimal Models of LRRK2 FunctionClinical Studies of LRRK2-Associated PD and Future ProspectsSmall-Molecule Inhibitors of LRRK2Structural Models of the LRRK2 Kinase DomainStrategies Used to Identify LRRK2 Kinase Inhibitors (Overview)ConclusionsTHERAPEUTIC POTENTIAL OF KINASES IN ASTHMAIntroductionMitogen-Activated Protein KinasesNonreceptor Protein Tyrosine KinasesReceptor Tyrosine KinasesPhosphatidylinositol-3 KinasesAGC KinasesIkB KinaseOther KinasesConclusions: Future DirectionsDEVELOPING TARGETED PET TRACERS IN THE ERA OF PERSONALIZED MEDICINEImaging and Pharmacodynamics Biomarkers in Drug DevelopmentGeneral Considerations for Development of 11C- and 18F-labeled PET TracersRadiolabeling Compounds with 11CRadiolabeling Compounds wiht 18FPET Imaging in the Clinic, Research, and Drug DevelopmentPET Tracer Kinetic Modeling for Quantification of Tracer UptakeConcluding RemarksMEDICINAL CHEMISTRY IN THE CONTEXT OF THE HUMAN GENOMEIntroductionDrugs Targeting KinasesDrugs Targeting PhosphatasesIn silico-Based Lead Discovery in the GPCR FamilyTargeting Epigenetic Regulation: Histone DemethylasesTargeting Epigenetic Regulation: Histone DeacetylasesA Family-Wide Approach to Poly(ADP-Ribose) PolymerasesFuture Drug Target Superfamilies: Ubiquitination and DeubiquitinationSummary and OutlookIndex